Clinical Trial

A clinical trial is a test on humans. It examines whether a new medication, a vaccine, or a treatment procedure actually works. Just as important is the question of what side effects occur. Beforehand, the substance was only examined in the laboratory and on animals. However, this preliminary stage says little about how a human body will react. That is why the trial on humans is the last and decisive step before permission to sell is granted. The procedure is precisely defined in advance and is monitored by authorities and independent ethics committees.

Why authorities approve nothing without trial data

Without such tests, no one would know whether a remedy helps or harms. People often get better on their own, even without treatment. A doctor who administers a new remedy and then observes improvement can therefore be mistaken. Only the comparison of many patients shows what is truly attributable to the medication.

Authorities such as the German Federal Institute for Drugs and Medical Devices or the US authority FDA therefore demand hard numbers. Approval is granted only if the benefit clearly outweighs the risks. This is the reason why medications take so long: from the first idea to the pharmacy, it often takes ten years or more. Only a small fraction of the tested substances even makes it to the end.

For companies, trials are therefore the largest cost block. They can cost several hundred million euros. If a trial fails in the final phase, a company often loses a large portion of its market value in a single day. Clinical trials are thus not only medicine, but also a major financial risk.

Phases, control group, and blinding

Clinical trials run in four phases. In Phase I, a few dozen volunteers take part, usually healthy ones. Here it is only about tolerability and the correct dosage. In Phase II, several hundred patients receive the remedy in order to gather initial indications of effectiveness. Phase III is the major decision-making phase, often with several thousand participants. Phase IV continues after approval and looks for rare side effects.

The most important trick is the control group. One half of the participants receives the real remedy, the other a sham medication without an active ingredient, a so-called placebo. Who ends up in which group is decided at random. This is called randomization, and it prevents, for example, all mild cases from ending up in one group.

In addition, neither patients nor doctors know who receives what. This blinding protects against self-deception on both sides. In the end, it is calculated whether the difference between the groups is large enough not to be merely chance. A common misconception: a trial never proves one hundred percent certainty. It only makes a result so unlikely to be due to chance that one can rely on it.

Clinical trials in stock market news and in the AI industry

In business news, clinical trials appear almost daily. Reports like “Phase III trial successful” cause pharmaceutical company stocks to rise sharply. Conversely, the share price plummets when a trial is discontinued. Anyone reading such news should pay attention to the phase and the number of participants. A good result with 30 people means much less than one with 5000.

The term is also becoming more important in the AI industry. Software that evaluates X-ray images or is meant to detect skin cancer is considered a medical device in Europe. Such programs must also prove their benefit in trials before clinics are allowed to use them. A model that performs well in the lab on old data can fail in a real hospital.

Conversely, AI is used to speed up trials themselves. Programs search patient records for suitable participants or predict which active ingredients have any chance at all. Anyone who knows the basic concepts therefore understands both pharma news and the promises of many AI startups in the healthcare sector better.